Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.81 |
| ▸ | PARP14 | Q460N5 | 3/20 | 0.81 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.81 |
| ▸ | TNKS | O95271 | 1/20 | 0.81 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.81 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.63 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.55 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631040 | 0.89 | PARP10 (1.00) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL8903435 | 0.88 | ALDH1A1 (0.66) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL15053820 | 0.88 | PARP10 (0.72) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL29436294 | 0.88 | ALDH1A1 (0.66) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL310329 | 0.88 | ALDH1A1 (0.66) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL2531295 | 0.87 | PARP10 (0.83) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL30434552 | 0.87 | PARP10 (0.83) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL619686 | 0.86 | AKR1C3 (0.77) | PARP10PARP14PARP15TNKSTNKS2 | |
| SCHEMBL8907997 | 0.86 | ALDH1A1 (0.63) | PARP10PARP14PARP15TNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL28772951 | 0.86 | PARP10 (0.80) | PARP10PARP14PARP15TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025102082-A1 | CARBOCYCLIC AND HETEROCYCLIC STAT3 INHIBITOR COMPOSITIONS AND METHODS | ALTAY THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2387/4885PARP14 2631/4885PARP15 2888/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | PARP10 3150/4885PARP14 3444/4885PARP15 3614/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2488/4885PARP14 2740/4885PARP15 2941/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2488/4885PARP14 2740/4885PARP15 2941/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PARP10 2954/4885PARP14 3129/4885PARP15 3373/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | PARP10 1953/4885PARP14 2091/4885PARP15 2198/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | PARP10 2488/4885PARP14 2740/4885PARP15 2941/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | PARP10 2932/4885PARP14 3030/4885PARP15 3241/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | PARP10 2488/4885PARP14 2740/4885PARP15 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.